Clinical trial · Interventional

Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer

A Single-Institution, Open-Label, Single-Arm phase1/2 Study of Measles Vaccine as Consolidation in Patients With Measles Virus-Positive, Stage 3B/4 Non-Small Cell Lung Cancer

NCT00828022CI-TRIAL-00001925SMC4692unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The objectives of the study are to assess the efficacy and safety of live, attenuated measles vaccine as consolidation therapy in patients with measles-positive, non-small cell lung cancer with locally-advanced (stage 3B with pleural effusion) or metastatic (stage 4) tumors in remission.

Conditions

Conditions (2)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Measles	—	UNRESOLVED	—
Non-Small Cell Lung Cancer	Lung Non-Small Cell Carcinoma	ALIAS	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
attenuated measles vaccine	Biological	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
To assess progression-free survival (PFS) and overall survival (OS) in patients with NSCLC in remission receiving subcutaneous live-attenuated measles virus vaccine as consolidation therapy in patients with measles-positive tumors.
timeFrame
2-years

Secondary outcomes (1)

measure
To evaluate additional measures of efficacy, safety, and disease/treatment-related symptoms.
timeFrame
2 years

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 80 Years

Show eligibility criteria text

Inclusion Criteria:

* Patients in remission after first-line chemotherapy

Exclusion Criteria:

* Progressive disease

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Mar 1, 2009
Primary completion: —
Completion: —
First posted: Jan 23, 2009
Last update posted: Jan 23, 2009
Enrollment: 15 (estimated)
Lead sponsor: Soroka University Medical Center OTHER
Keywords: measles-positive NSCLC, measles vaccine, consolidation, Stage 3B with pleural effusion or stage 4 non-small cell lung cancer in remission

Data updated 22 days agoSource updated Jan 23, 2009source: clinicaltrials

Locations

Locations by country (1)

Country	Sites	Recruiting
Israel	1	0

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.